Out the window.

That’s where our knowledge on appropriate radiation dosing and fraction for non-small cell lung cancer (NSCLC) should go now that PD-1 targeted agents are in the mix. This article in Annals of Oncology explains how all kinds of things affect the efficacy of PD-1 inhibition and how radiation affects all those kinds of things. Basically, if you think you understand all the radiation biology surrounding PD-1 targeted agents, think again.